New heartburn drug put to the test – with and without food

NCT ID NCT07364838

Completed Symptom relief Sponsor: Daewon Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called DW4421 in 24 healthy adults to see how food changes the way the body absorbs it. The goal is to learn whether the drug should be taken with or without food for future studies. This is a safety and dosing study, not a test of whether the drug works for GERD.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DW4421
What this could lead to: If successful, this could help develop a new medication for heartburn and acid reflux (GERD) that is taken with or without food.
What could go wrong: This is a very early Phase 1 trial in only 24 healthy people, not patients. It only tests how food affects the drug, not whether it works for GERD. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD (GASTROESOPHAGEAL REFLUX DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GERD (GASTROESOPHAGEAL REFLUX DISEASE)

Contacts and locations

Locations

Chungbuk National University Hospital

Cheongju-si, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.